|
Pronunciation |
|
(meth
i kloe THYE a
zide) |

|
|
U.S. Brand
Names |
|
Aquatensen®;
Enduron® |

|
|
Generic
Available |
|
Yes |

|
|
Pharmacological Index |
|
Diuretic, Thiazide |

|
|
Use |
|
Management of mild to moderate hypertension; treatment of edema in congestive
heart failure and nephrotic syndrome |

|
|
Pregnancy Risk
Factor |
|
B |

|
|
Contraindications |
|
Hypersensitivity to methyclothiazide or any component, thiazides, or
sulfonamide-derived drugs; anuria; renal decompensation |

|
|
Warnings/Precautions |
|
Avoid in severe renal disease (ineffective). Electrolyte disturbances
(hypokalemia, hypochloremic alkalosis, hyponatremia) can occur. Use with caution
in severe hepatic dysfunction; hepatic encephalopathy can be caused by
electrolyte disturbances. Gout can be precipitate in certain patients with a
history of gout, a familial predisposition to gout, or chronic renal failure.
Cautious use in diabetics; may see a change in glucose control. Hypersensitivity
reactions can occur. Can cause SLE exacerbation or activation. Use with caution
in patients with moderate or high cholesterol concentrations. Photosensitization
may occur. Correct hypokalemia before initiating therapy. |

|
|
Adverse
Reactions |
|
1% to 10%:
Cardiovascular: Orthostatic hypotension
Endocrine & metabolic: Hypokalemia
Dermatologic: Photosensitivity
Gastrointestinal: Anorexia, epigastric distress
<1% (Limited to important or life-threatening symptoms): Necrotizing
angiitis, vasculitis, cutaneous vasculitis, erythema multiforme, Stevens-Johnson
syndrome, aplastic anemia, hemolytic anemia, leukopenia, agranulocytosis,
thrombocytopenia, hepatic function impairment, respiratory distress
|

|
|
Overdosage/Toxicology |
|
Symptoms of overdose include hypermotility, diuresis, lethargy
GI decontamination and supportive care; fluids for hypovolemia
|

|
|
Drug
Interactions |
|
Angiotensin-converting enzyme inhibitors: Increased hypotension if
aggressively diuresed with a thiazide diuretic.
Beta-blockers increase hyperglycemic effects in Type 2 diabetes mellitus.
Cyclosporine and thiazides can increase the risk of gout or renal toxicity;
avoid concurrent use.
Digoxin toxicity can be exacerbated if a thiazide induces hypokalemia or
hypomagnesemia.
Lithium toxicity can occur by reducing renal excretion of lithium; monitor
lithium concentration and adjust as needed.
Neuromuscular blocking agents can prolong blockade; monitor serum potassium
and neuromuscular status.
NSAIDs can decrease the efficacy of thiazides reducing the diuretic and
antihypertensive effects. |

|
|
Mechanism of
Action |
|
Inhibits sodium reabsorption in the distal tubules causing increased
excretion of sodium and water, as well as, potassium and hydrogen
ions |

|
|
Pharmacodynamics/Kinetics |
|
Onset of diuresis: Oral: 2 hours
Peak effect: 6 hours
Duration: ~1 day
Distribution: Crosses the placenta; appears in breast milk
Elimination: Unchanged in urine |

|
|
Usual Dosage |
|
Adults: Oral:
Hypertension: 2.5-5 mg/day; may add another antihypertensive if 5 mg is not
adequate after a trial of 8-12 weeks of therapy |

|
|
Monitoring
Parameters |
|
Blood pressure, fluids, weight loss, serum potassium |

|
|
Cardiovascular
Considerations |
|
Thiazide diuretics are effective first-line therapeutic agents in the
management of hypertension and have proven to be of benefit in terms of
cardiovascular outcome. They may act synergistically to lower blood pressure
when combined with an ACE inhibitor or beta-blocker. The initial concern about
thiazide diuretic-induced hypokalemia, glucose intolerance, and lipid profiles
does not appear to be of substantial clinical consequence in the treatment of
hypertension. The benefits of this class of agents in the treatment of
hypertension is established and compares well with other first-line therapeutic
agents. |

|
|
Mental Health: Effects
on Mental Status |
|
May cause drowsiness |

|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
May rarely cause agranulocytosis; use caution with clozapine and
carbamazepine; may cause photosensitivity; use psychotropics with caution; may
decrease lithium clearance resulting in an increase in serum lithium levels and
potential lithium toxicity; monitor serum lithium levels |

|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |

|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |

|
|
Patient
Information |
|
Take exactly as directed - with meals. May take early in day to avoid
nocturia. Include bananas or orange juice in daily diet but do not take dietary
supplements without advice or consultation of prescriber. Do not use alcohol or
OTC medication without consulting prescriber. Weigh weekly at the same time, in
the same clothes. Report weight gain >5 lb/week. May cause dizziness or
weakness; change position slowly when rising from sitting or lying position and
avoid driving or tasks requiring alertness until response to drug is known. You
may experience nausea or loss of appetite (small frequent meals may help),
impotence (reversible), constipation (fluids, exercise, dietary fiber may help),
photosensitivity (use sunscreen, wear protective clothing and eyewear, and avoid
direct sunlight). This medication does not replace other antihypertensive
interventions; follow instructions for diet and lifestyle changes. Report
flu-like symptoms, headache, joint soreness or weakness, difficulty breathing,
skin rash, or excessive fatigue, swelling of extremities, or difficulty
breathing. Pregnancy/breast-feeding precautions: Do not get pregnant
while taking this medication; use appropriate barrier contraceptive measures.
Consult prescriber if breast-feeding. |

|
|
Nursing
Implications |
|
Assess weight, I & O reports daily to determine fluid loss; take blood
pressure with patient lying down and standing |

|
|
Dosage Forms |
|
Tablet: 2.5 mg, 5 mg |

|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|